Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
复制标题
DOI：
10.1016/j.bone.2009.07.008
复制
发表时间：
2009-11-01
期刊：
影响因子：
4.1
通讯作者：
Christiansen, Claus
中科院分区：
文献类型：
--
作者：
Henriksen, Dennis B.;Alexandersen, Peter;Christiansen, Claus
我们以前已经表明，重复给药胰高血糖素样肽-2（GILP-2）在晚上10点在绝经后妇女14天的结果在夜间骨吸收的剂量依赖性降低，通过s-CTX评估。与此相反，骨形成，如血清骨钙素评估，似乎是不受外源性GLP-2治疗，至少超过14 day.The本研究延长观察期至4个月。该研究是一项双盲安慰剂对照剂量范围试验，比较了三种不同剂量的GLP-2（0.4 mg、1.6 mg和3.2 mg GLP-2，每晚给药）与盐水对照注射。我们检查了安全性和耐受性，以及对骨转换生化标志物的影响和对骨矿物质密度的影响。注射0.4 mg，1.6 mg和3.2 mg GLP-2导致夜间s-CTX升高的类似降低，在治疗第120天，AUC（0- 10 H）与安慰剂的平均差异约为-150%*h（P
We have previously shown that repeated dosing of glucagon-like peptide-2 (GILP-2) at 10 p.m. in postmenopausal women for 14 days results in a dose-dependent decrease in the nocturnal bone resorption, as assessed by s-CTX. In contrast, bone formation, as assessed by serum osteocalcin, appeared to be unaffected by treatment with exogenous GLP-2, at least over 14 days.The present study extends the observation period to four months. The study was a double-blind placebo-controlled dose-ranging trial comparing three different doses of GLP-2 (0.4 mg, 1.6 mg and 3.2 mg GLP-2, administered nightly) against a saline control injection. We examined safety and tolerability, and the effects on biochemical markers of bone turnover and the effect on bone mineral density.Injection of 0.4 mg, 1.6 mg and 3.2 mg GLP-2 resulted in similar reduction in the nocturnal rise of s-CTX, at Treatment Day 120 the mean difference to placebo was approximately -150%*h at AUC(0-10H) (P